Toxicokinetics of perfluorooctane sulfonate in rainbow trout (Oncorhynchus mykiss).

Environ Toxicol Chem

Office of Research and Development, National Health and Environmental Effects Research Laboratory, Mid-Continent Ecology Division, US Environmental Protection Agency, Duluth, Minnesota, USA.

Published: March 2016

Rainbow trout (Oncorhynchus mykiss) confined to respirometer-metabolism chambers were dosed with perfluorooctane sulfonate (PFOS) by intra-arterial injection and sampled to obtain concentration time-course data for plasma and either urine or expired water. The data were then analyzed using a 2-compartment clearance-volume model. Renal and branchial clearance rates (mL/d/kg) determined for all experiments averaged 19% and 81% of total clearance, respectively. Expressed as mean values for all experiments, the steady-state volume of distribution was 277 mL/kg and the terminal half-life was 86.8 d. Additional animals were exposed to PFOS in water, resulting in an average calculated branchial uptake efficiency of 0.36%. The renal clearance rate determined in the present study is approximately 75 times lower than that determined in earlier studies with perfluorooctanoate (PFOA). Previously, it was suggested that PFOA is a substrate for membrane transporters in the trout kidney. The present study suggests that glomerular filtration may be sufficient to explain the observed renal clearance rate for PFOS, although a role for membrane transporters cannot be ruled out. These findings demonstrate that models developed to predict the bioaccumulation of perfluoroalkyl acids by fish must account for differences in renal clearance of individual compounds.

Download full-text PDF

Source
http://dx.doi.org/10.1002/etc.3230DOI Listing

Publication Analysis

Top Keywords

renal clearance
12
perfluorooctane sulfonate
8
rainbow trout
8
trout oncorhynchus
8
oncorhynchus mykiss
8
clearance rate
8
membrane transporters
8
clearance
5
toxicokinetics perfluorooctane
4
sulfonate rainbow
4

Similar Publications

Caffeine consumption is regarded as a widespread phenomenon, and its usage has continued to increase. In addition, the growing usage of antidepressants worldwide and increase in mental health disorders were shown in recent statistical analyses conducted by the World Health Organisation. The coadministration of caffeine and antidepressants remains a concern due to potential interactions that can alter a patient's response to therapy.

View Article and Find Full Text PDF

Preserved ratio impaired spirometry, airflow obstruction, and their trajectories in relationship to chronic kidney disease: a prospective cohort study.

Sci Rep

January 2025

Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, No.2, Xihuan South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing, China.

Spirometry findings, such as restrictive spirometry and airflow obstruction, are associated with renal outcomes. Effects of spirometry findings such as preserved ratio impaired spirometry (PRISm) and its trajectories on renal outcomes are unclear. This study aimed to investigate the impact of baseline and trajectories of spirometry findings on future chronic kidney disease (CKD) events.

View Article and Find Full Text PDF

Stem cells prevent long-term deterioration of renal function after renal artery revascularization in a renovascular hypertension model in rats.

Sci Rep

January 2025

Renal Division, Department of Medicine, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781, São Paulo, SP, 04039-032, Brazil.

Partial stenosis of the renal artery causes renovascular hypertension (RVH) and is accompanied by chronic renal ischemia, resulting in irreversible kidney damage. Revascularization constitutes the most efficient therapy for normalizing blood pressure (BP) and has significant benefits for renal function; however, the tissue damage caused by chronic hypoxia is not fully reversed. Mesenchymal stem cells (MSCs) have produced discrete results in minimizing RVH and renal tissue and functional improvements since the obstruction persists.

View Article and Find Full Text PDF

A Population Pharmacokinetic Analysis to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Iberdomide.

J Pharm Sci

January 2025

Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.

Iberdomide, a novel potent cereblon E3 ligase modulator, is under investigation for multiple myeloma. This study assessed how renal impairment (RI) affects iberdomide pharmacokinetics (PK). Twenty-six subjects with varying renal function, including those with severe renal impairment and those requiring intermittent hemodialysis (IHD), received a single oral 1 mg dose of iberdomide.

View Article and Find Full Text PDF

Based on the fact that beta-lactam antibiotics demonstrate time-dependent killing, different dosing strategies have been implemented to increase the time that free (f) (unbound) antibiotic concentrations remain above the Minimal Inhibitory Concentration (MIC), including prolonged and continuous infusion. Multiple studies have been performed that compared continuous with traditional intermittent infusion to improve outcomes in patients with severe sepsis and/or septic shock. These studies have yielded inconsistent results for patients as measured by clinical response to treatment and mortality due to heterogeneity of included patients, pathogens, dosing strategies and the absence of Therapeutic Drug Monitoring (TDM).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!